Triple negative breast cancer means that your cancer is not being fueled by any of the three main types of receptorsestrogen, progesterone nor the Her2 protein. Because of this, the cancer won’t respond to certain targeted therapies including hormone therapy or Her2-targeted agents like Herceptin. Chemotherapy is typically the treatment and there are several options.
Triple negative breast cancer is an aggressive form of the disease and if the cancer is advanced, your doctor may also recommend participation in a clinical trial that involves immunotherapy or targeted therapies.
Is My Cancer Really Triple-Negative?Read More
This excitement stems from the fact that HER2-low breast cancers are targetable with a recently new FDA-approved Enhertu (Fam-trastuzumab deruxtecan-nxki). It appears that Enhertu is extremely effective for appropriate patients and can greatly improve their quality of life and help them live longer.
Therefore, it is exceedingly important to discuss with your physician about your HER2 status.